Found: 15
Select item for more details and to access through your institution.
Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program.
- Published in:
- Cardiovascular Diabetology, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12933-023-01797-5
- By:
- Publication type:
- Article
Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 6, p. 2446, doi. 10.1111/dom.15566
- By:
- Publication type:
- Article
Impact on glycated haemoglobin and body weight changes after stopping tirzepatide for 4 weeks in the SURPASS‐1 monotherapy trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 1, p. 396, doi. 10.1111/dom.15325
- By:
- Publication type:
- Article
Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 9, p. 2553, doi. 10.1111/dom.15140
- By:
- Publication type:
- Article
Relative contribution of basal and postprandial hyperglycaemia stratified by HbA1c categories before and after treatment intensification with dulaglutide.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 6, p. 1365, doi. 10.1111/dom.13662
- By:
- Publication type:
- Article
Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12‐month follow‐up in a real‐world setting in the United States.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 4, p. 920, doi. 10.1111/dom.13603
- By:
- Publication type:
- Article
Dulaglutide 1.5 mg as an add‐on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 6, p. 1461, doi. 10.1111/dom.13252
- By:
- Publication type:
- Article
Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 7, p. 953, doi. 10.1111/dom.12902
- By:
- Publication type:
- Article
Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 330, n. 17, p. 1631, doi. 10.1001/jama.2023.20294
- By:
- Publication type:
- Article
Exit Interviews Examining the Patient Experience in Clinical Trials of Tirzepatide for Treatment of Type 2 Diabetes.
- Published in:
- Patient, 2022, v. 15, n. 3, p. 367, doi. 10.1007/s40271-022-00578-8
- By:
- Publication type:
- Article
RÉGIMEN CON INSULINA LISPRO MIX 25 VERSUS INSULINA GLARGINA PARA LA DIABETES TIPO 2.
- Published in:
- Medicina (Buenos Aires), 2012, v. 72, n. 3, p. 235
- By:
- Publication type:
- Article
Tirzepatide Improved Health-Related Quality of Life Compared with Insulin Lispro in Basal Insulin-Treated Adults with Type 2 Diabetes and Inadequate Glycaemic Control: A Randomised Controlled Phase 3b Trial (SURPASS-6).
- Published in:
- Diabetes Therapy, 2024, v. 15, n. 9, p. 2039, doi. 10.1007/s13300-024-01620-8
- By:
- Publication type:
- Article
Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme.
- Published in:
- Diabetes Therapy, 2023, v. 14, n. 11, p. 1833, doi. 10.1007/s13300-023-01451-z
- By:
- Publication type:
- Article
Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3.
- Published in:
- Diabetes Therapy, 2023, v. 14, n. 5, p. 925, doi. 10.1007/s13300-023-01398-1
- By:
- Publication type:
- Article
Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials.
- Published in:
- Diabetes Care, 2023, v. 46, n. 11, p. 1986, doi. 10.2337/dc23-0872
- By:
- Publication type:
- Article